Tissue Regenix dCELL to be put through clinical trial

The effectiveness of Tissue Regenix's dCELL dermis matrix is being assessed in a clinical trial by the University Hospital of South Manchester NHS Foundation Trust.

The work will involve a number of six week trials on 50 healthy human patients in order to assess the responsiveness of acute wounds to clarify if the solution improves the closure of acute wounds in comparison to "normal" wound healing.

Research will aim to understand the mechanism of action achieved by the dCELL dermis in treating acute wounds by identifying the cell types involved and examining the genomic profile of the healing process.

Dr Ardeshir, clinician scientist at the University of Manchester will lead the work, with the drug working by taking human donor skin and removing the DNA and cells through the patented dCELL process.

This will leave a dermis matrix that can be placed over the wound to aid natural healing by drawing the patient's own cells to the area of the wound.

The potential applications of this process are wide-ranging and can address a number of clinical needs including vascular disease, heart valve replacement and knee repair.

Antony Odell, managing director, Tissue Regenix Group, said: "We are delighted that this clinical trial can now proceed. Finding more effective ways to treat acute wounds could significantly improve the efficacy and speed of patient recovery times and save the NHS and other healthcare providers' significant sums of money.

"This builds on the work we have already been undertaking in collaboration with Dr Bayat and his team in Manchester on chronic wounds, with a clinical study which investigated successfully the efficacy of Tissue Regenix dCELL dermis matrix in healing chronic wounds such as venous ulcers."

Posted by Ben Evans